Indonesian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Halaman 1 dari 334 hasil
A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
The primary objective of this study is to determine the plasma pharmacokinetics (PK) of quizartinib and its pharmacologically active metabolite AC886 after a single oral dose of 30 mg in participants with moderate hepatic impairment (HI) (as defined by National Cancer Institute-Organ Dysfunction
Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
All eligible subjects must be relapsed or refractory to at least 2 prior lines of therapy, one of which must have included an inhibitor of B-cell receptor signaling (approved Bruton's tyrosine kinase inhibitor [BTKi] or Phosphoinositide 3-kinase inhibitor [PI3Ki]) or venetoclax. The dose escalation
Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
Donafenib is a multikinase inhibitor which is acting on various cellular pathways involved in the genesis of acute myeloid leukemia (AML). Donafenib is therefore a promising candidate for improvement of chemotherapy results in AML. This clinical trial evaluates the safety and pharmacokinetics of
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
Acute myeloid leukemia is a malignancy that is still fatal for the majority of patients. Besides age, the genetic configuration of AML blasts is one of the strongest prognostic factors. Patients with mutations in the core-binding factor (CBF) genes have the best prognosis, however a considerable
Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
Flumatinib + hyper-CVAD (younger than 60):
Induction therapy: Flumatinib 600mg per day, on an empty stomach; For cycles 1, 3, 5, and 7: cyclophosphamide (CTX) 300 mg/m² is given intravenously over 3 h every 12 h for six doses on days 1-3; a continuous daily infusion of sodium mercaptoethanesulfonate
The EMPATHY Pilot Study
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
The evolution in the understanding of the biology of Chronic Myeloid Leukemia (CML), that eventually translated into highly effective molecular targeted therapies, is unparalleled in cancer medicine. This knowledge led the development of a number of orally active molecule tyrosine kinase inhibitors
Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
PRE-PHASE: Patients may receive corticosteroids and/or hydroxyurea at the discretion of the treating physician prior to beginning induction therapy. A seven-day corticosteroid pre-phase, which can include days of corticosteroid receipt prior to protocol registration, will precede initiation of TKI
Value of CD26 Positive Leukemic Stem Cell in Myeloproliferative Neoplasm
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
Classic Myeloproliferative neoplasms (MPNs) are a heterogeneous group of diseases including Chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) (Levine et al., 2007).
According to WHO 2016 classification which also included chronic
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
This study is being conducted in three parts: Phase Ia, Phase Ib and Phase II, disease-specific expansion cohorts. Phase Ia explored escalating doses of a monotherapy of a novel Bruton's Tyrosine Kinase (BTK) inhibitor, DTRMWXHS-12. Phase Ib explored two combination therapies, DTRM-505 (DTRMWXHS-12
A Treatment Study Protocol for Participants 1-45 Years With Acute Lymphoblastic Leukaemia
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
ALLTogether is a European clinical treatment study for acute lymphoblastic leukaemia (ALL) in children and young adults. The aims are to improve survival and quality of survival for children and young adults with ALL. In young people, ALL has excellent outcome with an overall survival of about 92%
Immunophenotyping and Xist Gene in AML
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
Acute myeloid leukemia (AML) is a heterogeneous disorder characterized by clonal expansion of myeloid progenitors (blasts) in the bone marrow and peripheral blood. with high mortality and variable prognosis. AML is the most common acute leukemia in adults, accounting for ~ 80 percent of cases in
A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
Gene Expression Profiles in CML Non-responders
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
The aim of this project is to use gene expression microarrays to detect expression profiles which may be associated with TKI resistance in order to better stratify CML patients and allow a more targeted approach to therapy. The project may also help elucidate the mechanism of resistance in those
ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
PRIMARY OBJECTIVE:
I. To determine the clinical activity of the combination of asciminib (ABL001) and a tyrosine kinase inhibitor (TKI) in patients with chronic myeloid leukemia (CML) in complete cytogenetic response (CCyR) but detectable BCR-ABL1 transcript.
SECONDARY OBJECTIVES:
I. To determine
Database tanaman obat terlengkap yang didukung oleh sains
- Bekerja dalam 55 bahasa
- Pengobatan herbal didukung oleh sains
- Pengenalan herbal melalui gambar
- Peta GPS interaktif - beri tag herba di lokasi (segera hadir)
- Baca publikasi ilmiah yang terkait dengan pencarian Anda
- Cari tanaman obat berdasarkan efeknya
- Atur minat Anda dan ikuti perkembangan berita, uji klinis, dan paten
Ketikkan gejala atau penyakit dan baca tentang jamu yang mungkin membantu, ketik jamu dan lihat penyakit dan gejala yang digunakan untuk melawannya.
* Semua informasi didasarkan pada penelitian ilmiah yang dipublikasikan
